Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial

• Published in: The lancet. Gastroenterology & hepatology Vol. 7; no. 3; p. 208
• Main Authors: Kaseb, Ahmed Omar, Hasanov, Elshad, Cao, Hop Sanderson Tran, Xiao, Lianchun, Vauthey, Jean-Nicolas, Lee, Sunyoung S, Yavuz, Betul Gok, Mohamed, Yehia I, Qayyum, Aliya, Jindal, Sonali, Duan, Fei, Basu, Sreyashi, Yadav, Shalini S, Nicholas, Courtney, Sun, Jing Jing, Singh Raghav, Kanwal Pratap, Rashid, Asif, Carter, Kristen, Chun, Yun Shin, Tzeng, Ching-Wei David, Sakamuri, Divya, Xu, Li, Sun, Ryan, Cristini, Vittorio, Beretta, Laura, Yao, James C, Wolff, Robert A, Allison, James Patrick, Sharma, Padmanee
• Format: Journal Article
• Language: English
• Published: Netherlands 01.03.2022
• Subjects: Aged; Alanine Transaminase - blood; Antineoplastic Agents, Immunological - administration & dosage; Antineoplastic Agents, Immunological - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Aspartate Aminotransferases - blood; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - surgery; Female; Humans; Ipilimumab - administration & dosage; Ipilimumab - adverse effects; Liver Neoplasms - drug therapy; Liver Neoplasms - surgery; Male; Middle Aged; Nivolumab - administration & dosage; Nivolumab - adverse effects; Perioperative Care; Progression-Free Survival

Hepatocellular carcinoma has high recurrence rates after surgery; however, there are no approved standard-of-care neoadjuvant or adjuvant therapies. Immunotherapy has been shown to improve survival in advanced hepatocellular carcinoma; we therefore aimed to evaluate the safety and tolerability of pe...